|
Utah
|
|
87-0447695
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Identification No.)
|
Large Accelerated Filer
x
|
Accelerated Filer
o
|
Non-Accelerated Filer
o
|
Smaller Reporting Company
o
|
Emerging Growth Company
o
|
|
|
(Do not check if a smaller reporting company)
|
|
|
Common Stock
|
|
50,198,833
|
Title or class
|
|
Number of Shares
Outstanding at October 31, 2017
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
September 30,
|
|
December 31,
|
||||
|
2017
|
|
2016
|
||||
Finished goods
|
$
|
80,708
|
|
|
$
|
63,852
|
|
Work-in-process
|
18,162
|
|
|
11,008
|
|
||
Raw materials
|
46,728
|
|
|
45,835
|
|
||
|
|
|
|
||||
Total
|
$
|
145,598
|
|
|
$
|
120,695
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Cost of goods sold
|
$
|
189
|
|
|
$
|
105
|
|
|
$
|
453
|
|
|
$
|
369
|
|
Research and development
|
110
|
|
|
51
|
|
|
262
|
|
|
147
|
|
||||
Selling, general, and administrative
|
893
|
|
|
347
|
|
|
2,168
|
|
|
1,397
|
|
||||
Stock-based compensation expense before taxes
|
$
|
1,192
|
|
|
$
|
503
|
|
|
$
|
2,883
|
|
|
$
|
1,913
|
|
|
Three Months
|
|
Nine Months
|
||||||||||||||||||
|
Net
Income
|
|
Shares
|
|
Per Share
Amount
|
|
Net
Income
|
|
Shares
|
|
Per Share
Amount
|
||||||||||
Period ended September 30, 2017:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Basic EPS
|
$
|
(3,569
|
)
|
|
50,150
|
|
|
$
|
(0.07
|
)
|
|
$
|
20,717
|
|
|
48,332
|
|
|
$
|
0.43
|
|
Effect of dilutive stock options and warrants
|
|
|
|
1,449
|
|
|
|
|
|
|
|
1,223
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Diluted EPS
|
$
|
(3,569
|
)
|
|
51,599
|
|
|
$
|
(0.07
|
)
|
|
$
|
20,717
|
|
|
49,555
|
|
|
$
|
0.42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Stock options excluded from the calculation of common stock equivalents as the impact was anti-dilutive
|
|
|
200
|
|
|
|
|
|
|
434
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Period ended September 30, 2016:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Basic EPS
|
$
|
973
|
|
|
44,447
|
|
|
$
|
0.02
|
|
|
$
|
12,615
|
|
|
44,346
|
|
|
$
|
0.28
|
|
Effect of dilutive stock options and warrants
|
|
|
|
553
|
|
|
|
|
|
|
|
417
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Diluted EPS
|
$
|
973
|
|
|
45,000
|
|
|
$
|
0.02
|
|
|
$
|
12,615
|
|
|
44,763
|
|
|
$
|
0.28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Stock options excluded from the calculation of common stock equivalents as the impact was anti-dilutive
|
|
|
408
|
|
|
|
|
|
|
864
|
|
|
|
|
|
Preliminary Allocation
|
||
|
Net Assets Acquired
|
|
||
|
Inventories
|
$
|
579
|
|
|
Intangibles
|
|
||
|
Developed technology
|
14,920
|
|
|
|
Customer list
|
120
|
|
|
|
Goodwill
|
6,381
|
|
|
|
|
|
||
|
Total net assets acquired
|
$
|
22,000
|
|
|
|
Preliminary Allocation
|
||
|
Net Assets Acquired
|
|
||
|
Inventories
|
$
|
1,023
|
|
|
Property and equipment
|
58
|
|
|
|
Intangibles
|
|
||
|
Developed technology
|
5,400
|
|
|
|
Customer list
|
200
|
|
|
|
Goodwill
|
159
|
|
|
|
|
|
||
|
Total net assets acquired
|
$
|
6,840
|
|
Assets Acquired
|
|
||
Trade receivables
|
$
|
4,054
|
|
Other receivables
|
6
|
|
|
Inventories
|
8,585
|
|
|
Prepaid expenses
|
630
|
|
|
Property and equipment
|
1,630
|
|
|
Other long-term assets
|
145
|
|
|
Intangibles
|
|
||
Developed technology
|
67,600
|
|
|
Customer lists
|
2,400
|
|
|
Trademarks
|
4,400
|
|
|
Goodwill
|
24,818
|
|
|
Total assets acquired
|
114,268
|
|
|
|
|
||
Liabilities Assumed
|
|
||
Trade payables
|
(1,790
|
)
|
|
Accrued expenses
|
(5,298
|
)
|
|
Deferred income tax liabilities - current
|
(701
|
)
|
|
Deferred income tax liabilities - noncurrent
|
(10,844
|
)
|
|
Total liabilities assumed
|
(18,633
|
)
|
|
|
|
||
Net assets acquired, net of cash received of $1,327
|
$
|
95,635
|
|
Assets Acquired
|
|
||
Inventories
|
$
|
2,455
|
|
Property and equipment
|
290
|
|
|
Intangibles
|
|
||
Developed technology
|
12,100
|
|
|
Trademarks
|
700
|
|
|
Customers Lists
|
400
|
|
|
Goodwill
|
2,555
|
|
|
|
|
||
Total assets acquired
|
$
|
18,500
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Net Sales
(1)
|
|
|
|
|
|
|
|
|
|
||||||
Cardiovascular
|
$
|
172,723
|
|
|
$
|
150,503
|
|
|
$
|
517,140
|
|
|
$
|
428,571
|
|
Endoscopy
|
6,614
|
|
|
6,472
|
|
|
19,815
|
|
|
17,552
|
|
||||
Total net sales
|
179,337
|
|
|
156,975
|
|
|
536,955
|
|
|
446,123
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Operating Income (Loss)
(1)
|
|
|
|
|
|
|
|
|
|
||||||
Cardiovascular
|
(1,207
|
)
|
|
1,858
|
|
|
14,239
|
|
|
19,385
|
|
||||
Endoscopy
|
2,086
|
|
|
1,129
|
|
|
5,611
|
|
|
2,889
|
|
||||
Total operating income
|
879
|
|
|
2,987
|
|
|
19,850
|
|
|
22,274
|
|
|
September 30, 2017
|
|
December 31, 2016
|
||||
2016 Term loan
|
$
|
87,500
|
|
|
$
|
145,000
|
|
2016 Revolving credit loans
|
184,000
|
|
|
180,000
|
|
||
2017 Debt facility
|
6,962
|
|
|
—
|
|
||
Less debt issuance costs
|
(522
|
)
|
|
(627
|
)
|
||
Total debt
|
277,940
|
|
|
324,373
|
|
||
Less current portion
|
16,962
|
|
|
10,000
|
|
||
Long-term portion
|
$
|
260,978
|
|
|
$
|
314,373
|
|
Years Ending
|
|
Future Minimum
|
||
December 31
|
|
Principal Payments
|
||
Remaining 2017
|
|
2,500
|
|
|
2018
|
|
19,462
|
|
|
2019
|
|
15,000
|
|
|
2020
|
|
17,500
|
|
|
2021
|
|
224,000
|
|
|
Total future minimum principal payments
|
|
$
|
278,462
|
|
Currency
|
Symbol
|
Forward Notional Amount
|
|
Euro
|
EUR
|
5,555
|
|
Swiss Franc
|
CHF
|
1,088
|
|
Danish Krone
|
DKK
|
7,775
|
|
British Pound
|
GBP
|
2,550
|
|
Mexican Peso
|
MXN
|
64,425
|
|
Swedish Krona
|
SEK
|
10,805
|
|
Currency
|
Symbol
|
Forward Notional Amount
|
|
Euro
|
EUR
|
21,801
|
|
British Pound
|
GBP
|
1,128
|
|
Chinese Yuan Renminbi
|
CNY
|
39,954
|
|
Mexican Peso
|
MXN
|
17,537
|
|
Brazilian Real
|
BRL
|
8,500
|
|
Australian Dollar
|
AUD
|
4,599
|
|
Hong Kong Dollar
|
HKD
|
11,000
|
|
Swiss Franc
|
CHF
|
278
|
|
Swedish Krona
|
SEK
|
6,007
|
|
Canadian Dollar
|
CAD
|
1,968
|
|
Singapore Dollar
|
SGD
|
3,585
|
|
Japanese Yen
|
JPY
|
178,500
|
|
South Korean Won
|
KRW
|
1,800,000
|
|
|
Amount of Gain/(Loss) recognized in OCI
|
|
|
Amount of Gain/(Loss) reclassified from AOCI
|
||||||||||
|
Three Months Ended September 30,
|
|
|
Three Months Ended September 30,
|
||||||||||
|
2017
|
2016
|
|
|
2017
|
2016
|
||||||||
Derivative instrument
|
|
|
Location in Statements of Income
|
|||||||||||
Interest rate swaps
|
$
|
1
|
|
$
|
(256
|
)
|
|
Interest expense
|
$
|
96
|
|
$
|
(153
|
)
|
|
|
|
|
|
|
|
||||||||
Foreign currency forward contracts
|
100
|
|
—
|
|
|
Revenue
|
(101
|
)
|
—
|
|
||||
|
|
|
|
Cost of goods sold
|
250
|
|
—
|
|
|
Amount of Gain/(Loss) recognized in OCI
|
|
|
Amount of Gain/(Loss) reclassified from AOCI
|
||||||||||
|
Nine Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
||||||||||
|
2017
|
2016
|
|
|
2017
|
2016
|
||||||||
Derivative instrument
|
|
|
Location in Statements of Income
|
|||||||||||
Interest rate swaps
|
$
|
(611
|
)
|
$
|
(1,503
|
)
|
|
Interest expense
|
$
|
(8
|
)
|
$
|
(519
|
)
|
|
|
|
|
|
|
|
||||||||
Foreign currency forward contracts
|
841
|
|
—
|
|
|
Revenue
|
(141
|
)
|
—
|
|
||||
|
|
|
|
Cost of goods sold
|
213
|
|
—
|
|
|
|
|
|
Three months ended September 30,
|
|
Nine months ended September 30,
|
||||||||||
|
|
|
|
2017
|
2016
|
|
2017
|
2016
|
||||||||
Derivative Instrument
|
|
Location in Statements of Income
|
|
|
|
|
|
|
||||||||
Foreign currency forward contracts
|
|
Other income (expense)
|
|
$
|
(1,459
|
)
|
$
|
(76
|
)
|
|
$
|
(4,150
|
)
|
$
|
(222
|
)
|
|
|
|
|
Fair Value Measurements Using
|
||||||||||||
|
|
Total Fair
|
|
Quoted prices in
|
|
Significant other
|
|
Significant
|
||||||||
|
|
Value at
|
|
active markets
|
|
observable inputs
|
|
unobservable inputs
|
||||||||
Description
|
|
September 30, 2017
|
|
(Level 1)
|
|
(Level 2)
|
|
(Level 3)
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Interest rate contracts (1)
|
|
$
|
4,388
|
|
|
$
|
—
|
|
|
$
|
4,388
|
|
|
$
|
—
|
|
Foreign currency contract assets, current and long-term (2)
|
|
$
|
1,289
|
|
|
$
|
—
|
|
|
$
|
1,289
|
|
|
$
|
—
|
|
Foreign currency contract liabilities, current and long-term (3)
|
|
$
|
(592
|
)
|
|
$
|
—
|
|
|
$
|
(592
|
)
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
Fair Value Measurements Using
|
||||||||||||
|
|
Total Fair
|
|
Quoted prices in
|
|
Significant other
|
|
Significant
|
||||||||
|
|
Value at
|
|
active markets
|
|
observable inputs
|
|
unobservable inputs
|
||||||||
Description
|
|
December 31, 2016
|
|
(Level 1)
|
|
(Level 2)
|
|
(Level 3)
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Interest rate contracts (1)
|
|
$
|
4,991
|
|
|
$
|
—
|
|
|
$
|
4,991
|
|
|
$
|
—
|
|
Foreign currency contract assets, current and long-term (2)
|
|
$
|
354
|
|
|
$
|
—
|
|
|
$
|
354
|
|
|
$
|
—
|
|
Foreign currency contract liabilities, current and long-term (3)
|
|
$
|
(464
|
)
|
|
$
|
—
|
|
|
$
|
(464
|
)
|
|
$
|
—
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Beginning balance
|
$
|
5,572
|
|
|
$
|
898
|
|
|
$
|
683
|
|
|
$
|
1,024
|
|
Contingent consideration liability recorded as the result of acquisitions (see Note 5)
|
5,500
|
|
|
—
|
|
|
10,400
|
|
|
—
|
|
||||
Fair value adjustments recorded to income during the period
|
20
|
|
|
(193
|
)
|
|
39
|
|
|
(136
|
)
|
||||
Contingent payments made
|
(15
|
)
|
|
(16
|
)
|
|
(45
|
)
|
|
(199
|
)
|
||||
Ending balance
|
$
|
11,077
|
|
|
$
|
689
|
|
|
$
|
11,077
|
|
|
$
|
689
|
|
Contingent consideration asset or liability
|
|
Fair value at September 30, 2017
|
|
Valuation technique
|
|
Unobservable inputs
|
|
Range
|
||
Revenue-based payments
|
|
$
|
11,077
|
|
|
Discounted cash flow
|
|
Discount rate
|
|
9.9% - 15%
|
contingent liability
|
|
|
|
|
Probability of milestone payment
|
|
100%
|
|||
|
|
|
|
|
|
Projected year of payments
|
|
2017-2037
|
||
|
|
|
|
|
|
|
|
|
||
Contingent receivable
|
|
$
|
528
|
|
|
Discounted cash flow
|
|
Discount rate
|
|
10%
|
asset
|
|
|
|
|
Probability of milestone payment
|
|
57%
|
|||
|
|
|
|
|
|
Projected year of payments
|
|
2017-2019
|
||
|
|
|
|
|
|
|
|
|
||
Contingent consideration asset or liability
|
|
Fair value at December 31, 2016
|
|
Valuation technique
|
|
Unobservable inputs
|
|
Range
|
||
Revenue-based payments
|
|
$
|
683
|
|
|
Discounted cash flow
|
|
Discount rate
|
|
9.9% - 15%
|
contingent liability
|
|
|
|
|
Probability of milestone payment
|
|
100%
|
|||
|
|
|
|
|
|
Projected year of payments
|
|
2017-2028
|
||
|
|
|
|
|
|
|
|
|
||
Contingent receivable
|
|
$
|
528
|
|
|
Discounted cash flow
|
|
Discount rate
|
|
10%
|
asset
|
|
|
|
|
Probability of milestone payment
|
|
57%
|
|||
|
|
|
|
|
|
Projected year of payments
|
|
2017-2019
|
|
2017
|
||
Goodwill balance at January 1
|
$
|
211,927
|
|
Effect of foreign exchange
|
2,418
|
|
|
Additions as the result of acquisitions
|
19,698
|
|
|
Goodwill balance at September 30
|
$
|
234,043
|
|
|
September 30, 2017
|
||||||||||
|
Gross Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net Carrying
Amount
|
||||||
Patents
|
$
|
15,972
|
|
|
$
|
(3,586
|
)
|
|
$
|
12,386
|
|
Distribution agreements
|
6,626
|
|
|
(4,248
|
)
|
|
2,378
|
|
|||
License agreements
|
23,804
|
|
|
(4,387
|
)
|
|
19,417
|
|
|||
Trademarks
|
16,220
|
|
|
(4,342
|
)
|
|
11,878
|
|
|||
Covenants not to compete
|
1,028
|
|
|
(961
|
)
|
|
67
|
|
|||
Customer lists
|
25,942
|
|
|
(17,461
|
)
|
|
8,481
|
|
|||
In-process technology
|
1,100
|
|
|
—
|
|
|
1,100
|
|
|||
|
|
|
|
|
|
||||||
Total
|
$
|
90,692
|
|
|
$
|
(34,985
|
)
|
|
$
|
55,707
|
|
|
December 31, 2016
|
||||||||||
|
Gross Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net Carrying
Amount
|
||||||
Patents
|
$
|
14,130
|
|
|
$
|
(3,165
|
)
|
|
$
|
10,965
|
|
Distribution agreements
|
6,626
|
|
|
(3,527
|
)
|
|
3,099
|
|
|||
License agreements
|
20,695
|
|
|
(3,422
|
)
|
|
17,273
|
|
|||
Trademarks
|
12,380
|
|
|
(3,330
|
)
|
|
9,050
|
|
|||
Covenants not to compete
|
1,028
|
|
|
(936
|
)
|
|
92
|
|
|||
Customer lists
|
22,261
|
|
|
(15,401
|
)
|
|
6,860
|
|
|||
Royalty agreements
|
267
|
|
|
(267
|
)
|
|
—
|
|
|||
|
|
|
|
|
|
||||||
Total
|
$
|
77,387
|
|
|
$
|
(30,048
|
)
|
|
$
|
47,339
|
|
•
|
risks relating to product recalls and product liability claims;
|
•
|
potential restrictions on our liquidity or our ability to operate our business within the term of our current credit agreement, and the consequences of any default under that agreement;
|
•
|
risks relating to protecting our intellectual property, including possible infringement of our intellectual property by third parties;
|
•
|
the assertion that our technology infringes the intellectual property rights of other parties, which could cause us to incur significant legal or licensing expenses and prevent us from selling our products;
|
•
|
our potential inability to successfully manage growth through acquisitions, including the inability to commercialize technology acquired through recent, proposed or future acquisitions;
|
•
|
expenditures relating to research, development, testing and regulatory approval or clearance of our products and the risk that such products may not be developed successfully or approved for commercial use;
|
•
|
greater governmental scrutiny and regulation of the medical device industry, including risks and expenses relating to the subpoena we received in October 2016 from the U.S. Department of Justice seeking information on our marketing and promotional practices;
|
•
|
reforms to the 510(k) process administered by the U.S. Food and Drug Administration (the "FDA");
|
•
|
risks relating to our products being used in unapproved circumstances;
|
•
|
investigations or actions under laws targeting fraud and abuse in the healthcare industry;
|
•
|
potential for significant adverse changes in, or our failure to comply with, governing regulations;
|
•
|
failure to comply with export control laws, customs laws, sanctions laws and other laws governing our operations in the U.S. and other countries, which could subject us to civil or criminal penalties, other remedial measures and legal expenses;
|
•
|
disruption of our critical information systems or material breaches in the security of our systems;
|
•
|
restrictions and limitations in our debt agreements and instruments, which could affect our ability to operate our business and our liquidity;
|
•
|
consequences of a covenant or payment breach under our debt agreements and instruments, which could lead to an unfavorable refinance or work-out arrangement or foreclosure on our assets;
|
•
|
increases in the price of commodity components;
|
•
|
negative changes in economic and industry conditions in the United States and other countries;
|
•
|
termination or interruption of relationships with our suppliers, or failure of such suppliers to perform;
|
•
|
fluctuations in exchange rates for Euro, CNY, GBP or other foreign currencies:
|
•
|
our need to generate sufficient cash flow to fund our debt obligations, capital expenditures, and ongoing operations;
|
•
|
the potential imposition of fines, penalties, or other adverse consequences if our employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations;
|
•
|
concentration of our revenues among a few products and procedures;
|
•
|
development of new products and technology that could render our existing products obsolete;
|
•
|
market acceptance of new products;
|
•
|
volatility in the market price of our common stock;
|
•
|
modification or limitation of governmental or private insurance reimbursement policies;
|
•
|
changes in healthcare markets related to healthcare reform initiatives;
|
•
|
failures to comply with applicable environmental laws;
|
•
|
changes in, or loss of, key personnel;
|
•
|
failure to report adverse medical events to the FDA or other regulatory authorities, which may subject us to sanctions that may materially harm our business;
|
•
|
work stoppage or transportation risks;
|
•
|
uncertainties associated with potential healthcare policy changes which may have a material adverse effect on our business and results of operations;
|
•
|
introduction of products in a timely fashion;
|
•
|
price and product competition;
|
•
|
availability of labor and materials;
|
•
|
cost increases;
|
•
|
fluctuations in and obsolescence of inventory; and
|
•
|
other factors referred to in the 2016 Form 10-K and other materials filed with the Securities and Exchange Commission.
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
Net sales
|
100%
|
|
100%
|
|
100%
|
|
100%
|
Gross profit
|
44.9
|
|
43.2
|
|
44.8
|
|
43.7
|
Selling, general and administrative expenses
|
30.5
|
|
33.9
|
|
31.6
|
|
31.1
|
Research and development expenses
|
7.2
|
|
7.3
|
|
7.2
|
|
7.5
|
Contingent consideration expense (benefit)
|
—
|
|
(0.1)
|
|
—
|
|
—
|
Acquired in-process research and development
|
6.7
|
|
0.2
|
|
2.3
|
|
0.1
|
Income from operations
|
0.5
|
|
1.9
|
|
3.7
|
|
5.0
|
Other income (expense) - net
|
(1.7)
|
|
(1.9)
|
|
0.9
|
|
(1.5)
|
Income (loss) before income taxes
|
(1.2)
|
|
—
|
|
4.6
|
|
3.5
|
Net income (loss)
|
(2.0)
|
|
0.6
|
|
3.9
|
|
2.8
|
|
|
|
Three Months Ended September 30,
|
|
|
|
Nine Months Ended September 30,
|
||||||||||||
|
% Change
|
|
2017
|
|
2016
|
|
% Change
|
|
2017
|
|
2016
|
||||||||
Cardiovascular
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Stand-alone devices
|
34.2%
|
|
$
|
68,724
|
|
|
$
|
51,195
|
|
|
45.6%
|
|
$
|
203,434
|
|
|
$
|
139,729
|
|
Custom kits and procedure trays
|
0.7%
|
|
30,436
|
|
|
30,223
|
|
|
2.2%
|
|
91,107
|
|
|
89,164
|
|
||||
Inflation devices
|
9.0%
|
|
20,033
|
|
|
18,371
|
|
|
8.3%
|
|
59,329
|
|
|
54,774
|
|
||||
Catheters
|
5.3%
|
|
31,751
|
|
|
30,139
|
|
|
12.2%
|
|
94,357
|
|
|
84,078
|
|
||||
Embolization devices
|
9.3%
|
|
12,252
|
|
|
11,207
|
|
|
8.8%
|
|
36,936
|
|
|
33,937
|
|
||||
CRM/EP
|
1.7%
|
|
9,527
|
|
|
9,368
|
|
|
18.9%
|
|
31,977
|
|
|
26,889
|
|
||||
Total
|
14.8%
|
|
172,723
|
|
|
150,503
|
|
|
20.7%
|
|
517,140
|
|
|
428,571
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Endoscopy
(1)
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Endoscopy devices
|
2.2%
|
|
6,614
|
|
|
6,472
|
|
|
12.9%
|
|
19,815
|
|
|
17,552
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Total
|
14.2%
|
|
$
|
179,337
|
|
|
$
|
156,975
|
|
|
20.4%
|
|
$
|
536,955
|
|
|
$
|
446,123
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||
Operating Income (Loss)
(1)
|
|
|
|
|
|
|
|
|
|||
Cardiovascular
|
(1,207
|
)
|
|
1,858
|
|
|
14,239
|
|
|
19,385
|
|
Endoscopy
|
2,086
|
|
|
1,129
|
|
|
5,611
|
|
|
2,889
|
|
Total operating income
|
879
|
|
|
2,987
|
|
|
19,850
|
|
|
22,274
|
|
Currency
|
Symbol
|
Forward Notional Amount
|
|
Euro
|
EUR
|
21,801
|
|
British Pound
|
GBP
|
1,128
|
|
Chinese Yuan Renminbi
|
CNY
|
39,954
|
|
Mexican Peso
|
MXN
|
17,537
|
|
Brazilian Real
|
BRL
|
8,500
|
|
Australian Dollar
|
AUD
|
4,599
|
|
Hong Kong Dollar
|
HKD
|
11,000
|
|
Swiss Franc
|
CHF
|
278
|
|
Swedish Krona
|
SEK
|
6,007
|
|
Canadian Dollar
|
CAD
|
1,968
|
|
Singapore Dollar
|
SGD
|
3,585
|
|
Japanese Yen
|
JPY
|
178,500
|
|
South Korean Won
|
KRW
|
1,800,000
|
|
Currency
|
Symbol
|
Forward Notional Amount
|
|
Euro
|
EUR
|
5,555
|
|
Swiss Franc
|
CHF
|
1,088
|
|
Danish Krone
|
DKK
|
7,775
|
|
British Pound
|
GBP
|
2,550
|
|
Mexican Peso
|
MXN
|
64,425
|
|
Swedish Krona
|
SEK
|
10,805
|
|
Exhibit No.
|
|
Description
|
3.1
|
|
Amended and Restated Articles of Incorporation dated February 28, 2017 (1)
|
|
|
|
3.2
|
|
Second Amended and Restated Bylaws (2)
|
|
|
|
10.1
|
|
Second Amendment to Second Amended and Restated Credit Agreement, dated March 20, 2017, entered into by and among Merit Medical Systems, Wells Fargo Bank, National Association and the lenders and subsidiary guarantors named therein (3)
|
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
101
|
|
The following financial information from the quarterly report on Form 10-Q of Merit Medical Systems, Inc. for the quarter ended September 30, 2017, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements of Income, (ii) Consolidated Balance Sheets, (iii) Consolidated Statements of Comprehensive Income, (iv) Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements
|
(1)
|
Incorporated by reference from the Annual Report on Form 10-K filed on March 1, 2017.
|
(2)
|
Incorporated by reference from the Current Report on Form 8-K filed on December 16, 2015.
|
(3)
|
Incorporated by reference from the Current Report on Form 8-K filed on March 20, 2017.
|
Date:
|
November 9, 2017
|
|
/s/ FRED P. LAMPROPOULOS
|
|
|
|
FRED P. LAMPROPOULOS
PRESIDENT AND CHIEF EXECUTIVE OFFICER
|
|
|
|
|
|
|
|
|
Date:
|
November 9, 2017
|
|
/s/ BERNARD J. BIRKETT
|
|
|
|
BERNARD J. BIRKETT
CHIEF FINANCIAL OFFICER
|
1.
|
Exceptions
. Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement:
|
To Indemnitee:
|
At Indemnitee’s residence address and facsimile number on the records of the Company from time to time.
|
Date: November 9, 2017
|
|
|
|
/s/ Fred P. Lampropoulos
|
|
Fred P. Lampropoulos
|
|
President and Chief Executive Officer
|
|
(principal executive officer)
|
|
Date: November 9, 2017
|
|
|
|
/s/ Bernard J. Birkett
|
|
Bernard J. Birkett
|
|
Chief Financial Officer
|
|
(principal financial officer)
|
|
Date: November 9, 2017
|
/s/ Fred P. Lampropoulos
|
|
Fred P. Lampropoulos
|
|
President and Chief Executive Officer
|
|
(principal executive officer)
|
Date: November 9, 2017
|
/s/ Bernard J. Birkett
|
|
Bernard J. Birkett
|
|
Chief Financial Officer
|
|
(principal financial officer)
|